Difference between revisions of "Lapatinib (Tykerb)"
m |
m |
||
| Line 27: | Line 27: | ||
*2009-05-15: Initial notice of compliance (unclear details) | *2009-05-15: Initial notice of compliance (unclear details) | ||
*2010-09-30: New indication in combination with letrozole for the treatment of post-menopausal patients with hormone receptor positive metastatic [[breast cancer]], whose tumours over express the ErbB2 (HER2) receptor, and who are suitable for endocrine therapy. | *2010-09-30: New indication in combination with letrozole for the treatment of post-menopausal patients with hormone receptor positive metastatic [[breast cancer]], whose tumours over express the ErbB2 (HER2) receptor, and who are suitable for endocrine therapy. | ||
| − | + | ==History of changes in PMDA indication== | |
| + | *2009-04-22: Initial approval for the treatment of inoperable or recurrent [[breast cancer]] with HER2 overexpression. | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' GW572016 | *'''Code name:''' GW572016 | ||
| Line 49: | Line 50: | ||
[[Category:FDA approved in 2007]] | [[Category:FDA approved in 2007]] | ||
[[Category:Health Canada approved in 2009]] | [[Category:Health Canada approved in 2009]] | ||
| + | [[Category:PMDA approved in 2009]] | ||
Revision as of 21:08, 10 June 2023
General information
Class/mechanism: EGFR/HER2 tyrosine kinase inhibitor; 4-anilinoquinazoline inhibitor of the intracellular tyrosine kinase domains of EGFR (epidermal growth factor receptor/ErbB1) and HER2 (human epidermal growth factor receptor 2/ErbB2), which drive proliferation in certain malignancies.
[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Lapatinib (Tykerb) patient drug information[4]
- Lapatinib (Tykerb) patient drug information (Chemocare)[5]
- Lapatinib (Tykerb) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 2007-03-13: Initial approval in combination with capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. (Based on EGF100151)
- 2010-01-29: Accelerated approval in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Based on EGF30008)
- 2018-12-06: Converted to regular approval.
History of changes in EMA indication
- 2008-06-10: Initial marketing authorization as Tyverb.
History of changes in Health Canada indication
- 2009-05-15: Initial notice of compliance (unclear details)
- 2010-09-30: New indication in combination with letrozole for the treatment of post-menopausal patients with hormone receptor positive metastatic breast cancer, whose tumours over express the ErbB2 (HER2) receptor, and who are suitable for endocrine therapy.
History of changes in PMDA indication
- 2009-04-22: Initial approval for the treatment of inoperable or recurrent breast cancer with HER2 overexpression.
Also known as
- Code name: GW572016
- Brand names: Abnib, Combinib, Etibo, Herduo, Herlapsa, Hertab, Lapanix, Lapatem, Tykerb, Tyverb